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The management of malignant biliary tumors (MBTs) is complex and requires a multidisciplinary approach. Guidelines and
methods of staging for biliary tumors have recently been released by main international societies, altering the clinical and
radiologic approach to this pathologic condition. The aim of the present review is to detail the updated role of imaging in
preoperative staging and follow-up and to illustrate clinical/therapeutic pathways. In addition, future perspectives on imaging
and targeted/embolization therapies are outlined.
ABBREVIATIONS
AJCC = American Joint Committee on Cancer, CBD = common bile duct, CC = cholangiocarcinoma, CMS = covered metal stent,
dCC = distal cholangiocarcinoma, FRL = future remnant liver, GBA = gallbladder adenocarcinoma, iCC = intrahepatic
cholangiocarcinoma, MBT = malignant biliary tumor, OLT = orthotopic liver transplantation, PBD = preoperative biliary drainage,
pCC = perihilar cholangiocarcinoma, PET = positron emission tomography, PVE = portal vein embolization, PV = portal vein, R0 =
negative resection margin, TNM = tumor/node/metastasis [staging]In recent years, joint clinical/radiologic management of
malignant biliary tumors (MBTs) has evolved to
improve patient survival and quality of life. MBTs
account for approximately 4% of all malignant neo-
plasms of the gastrointestinal tract and are generally
characterized by poor prognosis (1), as fewer than 20%
of patients are suitable candidates for curative treatment
(2,3). Cholangiocarcinoma (CC) and gallbladder adeno-
carcinoma (GBA) are the most common biliary tumors.27:1056–1069
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le@hotmail.comGuidelines for classification, imaging, staging, and
management of hepatobiliary cancers have been recently
updated by the National Comprehensive Cancer Net-
work (4). Although the American College of Radiology
has released criteria regarding radiologic management of
benign and malignant biliary obstruction (5,6), there
remains a paucity of universal radiologic guidelines
(7–10) regarding management of malignant biliary neo-
plasms. Technical aspects and recommendations regard-
ing biliary drainage in malignant biliary obstruction
have been published by major endoscopic societies
(American Society of Gastrointestinal Endoscopy and
European Society of Gastrointestinal Endoscopy) and
interventional radiologic societies (Cardiovascular and
Interventional Radiological Society of Europe and Soci-
ety of Interventional Radiology) (9–12). Asian-Pacific
guidelines focused on the endoscopic and interventional
management of hilar CC (13).
It is recognized that imaging studies and clinical
workup—and, consequently, treatment protocols—will
vary according to the patient’s clinical status and tumor
staging. An integrated approach involving surgery,
chemotherapy, radiation therapy, and new interven-
tional radiologic techniques represents the developing
frontier of therapeutic options. In this institutional
review board–approved review, we seek to review the
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ques regarding the most common MBTs.CC: CLASSIFICATION, STAGING, AND
IMAGING
CCs comprise all tumors originating from the bile-duct
epithelial sheet. More than 90% of these have histologic
features of adenocarcinoma and are classified according
to their pattern of growth: (i) mass-forming, (ii) peri-
ductal infiltrating, (iii) intraductal-growing, or (iv) unde-
fined, meaning more than one of the aforementioned
types (eg, mass-forming and intraductal-growing) (14).
Recent evidence underlined that the mass-forming,
periductal infiltrating type was associated with a worse
prognosis than other types, with higher recurrence rates
after resection (14).
Because of mucin production and the infiltrating
nature, bile duct filling defects evident on imaging may
indicate thrombus, redundant mucin, or bile duct calculi.
CCs may develop in any site of the biliary tree and are
currently classified as intrahepatic, perihilar, and distal
(the latter two types are also defined as extrahepatic),
with anatomic boundaries as follows: (i) the second-
order bile ducts delimit intrahepatic CC (iCC) from
perihilar CC (pCC); (ii) the cystic duct is the point of
distinction between pCC and distal CC (dCC); and (iii)
the ampulla of Vater is the distal landmark of dCC (of
note, tumors of the ampulla of Vater are considered
separately from CC).
iCC
Usually, iCC is primarily detected at imaging as an
isolated intrahepatic mass, and the differential diagnosis
for these appearances includes hepatocellular carcinoma.
Computed tomography (CT) and magnetic resonance
(MR) imaging are helpful for diagnosis and staging of
the primary tumor, but both imaging techniques have
low specificity; CT demonstrates superior performance
in depicting vascular involvement (14). The key pattern
for diagnosis is that the iCC increasingly enhances
during the arterial, venous, and particularly the
delayed phase (Fig 1). On the contrary, hepatocellular
carcinoma is characterized by brisk contrast
enhancement during the arterial phase and prompt
washout in the delayed phase (14). Recent studies
(15,16) found that adverse prognostic factors in iCC
include the number of lesions, vascular invasion, and
nodal involvement (ie, tumor/node/metastasis [TNM]
nodal stage N1). Interestingly, tumor size has not clearly
been shown to be relevant (15,16), and this is recognized
in the American Joint Committee on Cancer (AJCC)
staging guidelines (17).
Farges et al (18) found the AJCC staging to be more
accurate in predicting outcome in patients with iCC
compared with other staging systems. Using the AJCCstaging, patients with stage I disease had a 5-year
survival rate of 62%, whereas patients with stage II
disease had a 27% 5-year survival rate (18). The overall
AJCC staging system is depicted in Table 1.
Complete surgical resection remains the only cura-
tive treatment for iCC, even though most patients are
not candidates for surgery. Multifocal tumors and
metastatic hilar lymphadenopathy are currently con-
sidered relative contraindications to surgery. Nodal
metastases beyond the porta hepatis and distant meta-
static disease contraindicate resection. Local factors
such as lymphovascular, perineural invasion and tumor
size 4 5 cm have also been reported as independent
factors of recurrence and reduce overall survival fol-
lowing resection (4).Extrahepatic CC
Extrahepatic CC is currently classified as pCC or dCC (3).
pCC. Three staging systems for pCC are available:
Bismuth–Corlette classification, Seventh Edition AJCC
TNM staging, and Jarnagin–Blumgart classification.
The Bismuth–Corlette system (19) is a long-established
method for the staging of this tumor, but it does not
include important prognostic pathologic factors such as
vascular invasion, lymph node involvement, distant
metastases, and liver atrophy. In addition, this system
remains deficient in predicting resectability and survival
(19). The AJCC Seventh Edition system was introduced
more recently and includes consideration of regional and
distant lymph node involvement and distant metastases.
The latest Jarnagin–Blumgart staging for resectable pCC
permits prediction of resectability and likelihood of
metastatic disease and survival (20). Accuracy of
prognostic prediction with this staging system has been
found to be superior to that seen with the TNM system (eg,
accuracy for stage II: Jarnagin–Blumgart, 78.6%; TNM,
56.3% [20]). A comparison between Jarnagin–Blumgart
staging and complete TNM staging is provided in Table 2.
Hilar CCs are classified in three stages (tumor stages T1–
T3) according to the location and extent of bile duct
involvement, presence of portal vein (PV) involvement,
and hepatic lobar atrophy. The total score is yielded by the
cumulative score (ie, 0, 1, or 2) of preoperative staging
(stage T1, T2, or T3), intraoperative findings (ie, differ-
entiation), and resection margin (ie, from a negative
resection margin [R0] to a resection margin positive for
macroscopic residual disease, or the presence of metastasis).
Each total score is assigned a prognosis with survival time:
for example, if the total score is 0 (stage I), survival is
estimated to be4 3 years; if the total score is 4 (stage III),
there is an inferior prognosis with survival r 1 year. The
complete staging system is described in Table 3.
pCC is usually well-detected by CT andMR imaging, and
these represent fundamental modalities for comprehensive
staging of the disease. MR cholangiopancreatography is
Figure 1. Images from a 73-year-old woman referred with anemia and fatigue, with a history of cholecystectomy and CBD stones.
(a) Axial contrast-enhanced CT in arterial phase shows mild enhancement of the lesion. Increasing enhancement is noted during
the venous (b) and delayed (c) phases. There is infiltration of the liver capsule (solid arrows, b) and infiltration of the PV branch for
segment IV (dashed arrow, b). No lymph nodes are evident, and there is no apparent distant metastasis, indicating stage III disease
(T3N0M0). US-guided biopsy confirmed the diagnosis of CC, and the patient underwent chemoradiation therapy. (d) Follow-up CT after
6 months of chemoradiation therapy shows shrinkage and morphologic change of the tumor (arrows), but multiple satellite lesions are
present throughout the liver parenchyma.
Cannavale et al ’ JVIR1058 ’ Updated Management of Malignant Biliary Tract Tumorsthe imaging modality of choice for pCC: its accuracy in
assessing local extent and resectability (vascular and
lymph node involvement) is as high as 95% and is
comparable to that of endoscopic retrograde cholangio-
pancreatography (ERCP). CT is fundamental in the
assessment of distant metastatic disease (peritoneum,
bone, lung). Resectability may be assessed with CT with
an accuracy rate ranging between 60% and 88% and
negative predictive values of 85%–100%; however,
lymph node metastasis detection is less accurate (accu-
racy of 58%) (14).
New imaging parameters to be assessed in pCC
include (i) whether the tumor involves the hilum withor without unilateral extension to second-degree
biliary ducts (stage T1), (ii) the presence of ipsilateral
PV branch involvement and/or ipsilateral lobe atrophy
(stage T2; Fig 2), and (iii) the presence of contralateral
PV branch involvement or contralateral lobe atrophy or
main or bilateral PV involvement (stage T3). (iv) Al-
though lymph node involvement is not assessed by the
Jarnagin–Blumgart staging system, it remains important
to detect local (ie, stage N1) or distant (ie, stage N2)
lymph node metastases. Resectability is determined by
the assessment of those criteria; when using the classic
Bismuth–Corlette classification, tumors of stage III/IV
are typically considered unresectable (Fig 3).
Table 1 . AJCC 7th Edition TNM Staging for Intrahepatic Cholangiocarcinoma
Final Stage Tumor Stage Node Stage Metastasis Stage
I T1: solitary tumor without vascular
invasion
N0: no regional lymph node metastasis M0: no distant metastasis
II T2a: solitary tumor with vascular
invasion
N0: no regional lymph node metastasis M0: no distant metastasis
T2b: multiple tumors with/without
vascular invasion
III T3: tumor perforating visceral peritoneum
or involving local extrahepatic structures
by direct invasion
N0: no regional lymph node metastasis M0: no distant metastasis
IVA T4: tumor with periductal invasion N0: no regional lymph node metastasis M0: no distant metastasis
Any N1: no regional lymph node metastasis M0: no distant metastasis
IVB Any Any M1: distant metastasis
AJCC ¼ American Joint Committee on Cancer; TNM ¼ tumor/node/metastasis [staging].
Table 2 . Jarnagin–Blumgart Classification and AJCC 7th Edition Staging System for Perihilar Cholangiocarcinoma
Jarnagin–Blumgart Classification AJCC 7th Ed. Staging
Stage Criteria Tumor Stage Node Stage Metastasis Stage Final Stage
T1 Tumor involving biliary
confluence with/
without unilateral
extension to second-
degree biliary ducts
T1: tumor confined to
bile duct with
extension up to
muscle layer or
fibrous tissue
N0: no regional lymph
node
M0: no distant
metastasis;
M1: distant
metastasis
(liver, perito-
neum,
bone, lung)
Stage I
T2 Tumor involving biliary
confluence with/
without unilateral
extension to second-
degree biliary ducts
and ipsilateral PV
involvement with/
without ipsilateral
hepatic lobe atrophy
T2a: tumor invades
beyond wall of
bile duct to sur-
rounding
fat tissue
T2b: tumor invades
adjacent hepatic
parenchyma
N0: no regional lymph
node
Stage II
T3 (i) Tumor involving
biliary confluence with/
without unilateral
extension to second-
degree biliary ducts; (ii)
unilateral extension to
second-degree biliary
ducts with contralateral
PV involvement; (iii)
unilateral extension to
second-degree biliary
ducts with contralateral
hepatic lobe atrophy;
or (iv) main/bilateral PV
involvement
T3: tumor invades
unilateral branches
of PV or
hepatic artery
T4: tumor invades
main PV
N0: no regional
lymph node
N1: regional lymph
node metastasis
(nodes along CBD,
cystic duct, hepatic
artery, PV
N2: metastasis to dis-
tant lymph nodes
(periaortic, perica-
val, SMA,
celiac trunk)
Stage IIIA
(T3N0M0)
Stage IIIB
(T1–T3, N1, M0)
Stage IVA
(T4, N0/1, M0)
Stage IVB
(any T, N2, M0;
any T, any N, M1)
AJCC ¼ American Joint Committee on Cancer; CBD ¼ common bile duct; PV ¼ portal vein; SMA ¼ superior mesenteric artery.
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bile duct (CBD) from the cystic duct to the ampulla of
Vater. It may present with similar clinical features as
pCC, although fever is more common in dCC. Typically,dCC may present with two predominant imaging
characteristics: (i) high-attenuation mass or thickened
wall (biliary intraepithelial neoplasia; Fig 4) and (ii)
low-attenuation polypoid mass (intraductal papillary
Table 3 . Scoring Criteria for New Staging System for Perihilar Cholangiocarcinoma
Score
Jarnagin–Blumgart
Classification Intraoperative Findings
Resection
Margin
Total
Score Stage Prognosis
Predicted
Survival (y)
0 T1 High/moderate
differentiation without
distant metastasis
R0 0 I Good 4 3
1 T2 Poor differentiation R1 1 II Moderate 1–3
2 T3 Distant metastasis R2 2–6 III Poor o 1
R0 ¼ negative resection margin; R1 ¼ resection margin positive for local disease.
Figure 2. Images from a 60-year-old woman presenting with jaundice. (a) Coronal T2-weighted MR image demonstrates an ill-defined
stricture at the level of the hilum (arrows) and intrahepatic bile duct dilation. (b) Axial T2-weighted image confirming the lesion
infiltrating the biliary confluence as well as the right main biliary duct (arrow). (c) Postcontrast T1-weighted fat-saturated image shows
the tumor infiltrating the periportal space, abutting—but not invading—the right PV (arrow), and clear of the main PV. The appearances
are consistent with a Bismuth–Corlette type II tumor. There is no evidence of local lymphadenopathy or metastatic disease, for a
classification of stage II disease (T2N0M0) according to Jarnagin–Blumgart and AJCC classification, amenable to surgical resection. No
cholangitis or other indications for preoperative biliary drainage were present. Therefore, an extended right hemihepatectomy was
performed. (d) There was no evidence of recurrence on CT at 2 years after resection.
Cannavale et al ’ JVIR1060 ’ Updated Management of Malignant Biliary Tract Tumorsneoplasms; however, the differential diagnosis includes the
benign counterpart, papilloma or papillomatosis) (14).
dCC is characterized by depth of invasion, pancreatic
invasion, and frequent lymph node metastasis; of note,
metastatic lymph node spread is more commonly observedin dCC than in iCC and pCC. Tumor depth invasion,
lymph node metastases (number of lymph nodes), peri-
neural microscopic vascular invasion (PV invasion), inva-
sion into the pancreas, and R0 resection were found to be
significant predictors of survival (3,21,22).
Figure 3. Images from a 65-year-old woman presenting with jaundice and pruritus. (a) Coronal T2-weighted MR cholangiopancreato-
graphy image demonstrates narrowing of the hepatic hilum (arrow) and intrahepatic bile duct dilation. The main pancreatic duct is also
dilated mainly as a result of chronic pancreatitis (arrowheads). (b) Axial and (c,d) coronal T2-weighted images demonstrate disease
extension to the bifurcation of the right and left hepatic ducts (arrows), consistent with Bismuth type IV disease. (e) Postcontrast CT
demonstrates an ill-defined mass that infiltrated the hepatic artery (black arrows) and the PV (arrowhead). No significant nodes or
metastases were detected, indicating stage IV disease (T4N0M0). Therefore, the tumor is considered inoperable. In view of the
intrahepatic strictures, the patient underwent PTC and bilateral stent implantation. (f) PTC via bilateral percutaneous approach was
performed, and two transpapillary 10-mm  10-cm Wallstent stents (Boston Scientific, Marlborough, Massachusetts) were inserted,
extending in the intrahepatic bile ducts. The percutaneous tracts were plugged with Gelfoam (Pharmacia & Upjohn, Kalamazoo,
Michigan). The patient was discharged without complications, and chemotherapy was commenced.
Volume 27 ’ Number 7 ’ July ’ 2016 1061The new Seventh Edition AJCC/Union for Interna-
tional Cancer Control staging system introduced staging
for dCC that is separate from that for pCC (Table 4).
The new dCC staging system considers assessment of the
following parameters by CT/MR imaging: (i) tumor
confined to the bile duct (stage T1); (ii) tumor invasion
beyond the wall of the bile duct (stage T2); (iii) tumor
invasion of the gallbladder, pancreas, duodenum, or
other adjacent organs without involvement of the celiac
axis or superior mesenteric artery (stage T3); (iv)
invasion of the celiac axis or superior mesenteric artery
(stage T4); (v) presence of regional (porta hepatis/
peripancreatic) lymph node involvement (stage N1);
and (vi) presence of distant metastases (stage M1).
GBA: Staging and Imaging
Tumor stage has been demonstrated as the strongest
prognostic factor for patients with GBA (4). A
nationwide analysis in the United States (23) showed
5-year survival rates of 60%, 39%, and 15% for stage 0, I,
and II GBA, respectively, with survival rates decreasingto 5% and 1% for patients with stage III and IV disease,
respectively.
Staging of GBA is made according to the revised 2010
AJCC document in which stage groupings have been
changed to distinguish hilar node involvement from
involvement of other nodes and to improve correlation
with resectability criteria and clinical outcome (3,23)
(Table 5). Limited surgical resection is often performed
in early-stage GBA (stage 0/I), whereas middle- to
advanced-stage GBA (stages II/III) often requires
extended resection (beyond segment IVb and V) and
bile duct resection. However, these treatments have
shown to increase perioperative morbidity and are
therefore performed only in selected cases (24).
Multidetector CT is the most frequently used ima-
ging technique for staging and assessment of local
invasion (accuracy rate, 84%). MR imaging/MR chol-
angiopancreatography may be considered as additional
imaging tests to better assess the bile duct and vascular
invasion. At imaging, GBA may appear as (i) intra-
luminal polypoid lesion (stage Tis, T1), (ii) focal or
Figure 4. Images from a 67-year-old man referred with jaundice and recurrent cholangitis. (a) Axial CT image in delayed phase shows
thickening of the distal CBD (solid arrows) with adjacent enlarged lymph node (dashed arrow). (b) CT coronal view shows that the
thickened wall (arrowheads) is attached to the pancreatic parenchyma (arrows). (c) T2-weighted MR cholangiopancreatography
sequence shows obstruction of the distal CBD and marked dilation of the intrahepatic bile ducts. The tumor was classified as stage IIA
(T3N0M0). (d) CT coronal view shows the presence of a metallic stent within the middistal CBD after ERCP. Note that the stent has been
placed distally to the hilum to allow resection. (e) Postsurgical coronal CT image shows the short biliary–jejunal anastomosis (arrow)
and the remainder of the pancreas anastomosed to the jejunum, with dilated pancreatic duct (arrowheads).
Table 4 . AJCC 7th Edition Staging System for Distal Cholangiocarcinoma
Final Stage Tumor Stage Node Stage Metastasis Stage
IA T1: tumor confined to bile duct N0: no regional lymph node
metastasis
M0: no distant metastasis
IB T2: tumor invades beyond wall of bile duct N0: no regional lymph node
metastasis
M0: no distant metastasis
IIA T3: tumor invades pancreas, duodenum, gallbladder, or
other adjacent organs without involvement of celiac
axis or SMA
N0: no regional lymph node
metastasis
M0: no distant metastasis
IIB T1–T3 N1: regional lymph node
metastasis present
M0: no distant metastasis
III T4: tumor involves celiac axis or SMA Any M0: no distant metastasis
IV Any Any M1: distant metastasis
AJCC ¼ American Joint Committee on Cancer; SMA ¼ superior mesenteric artery.
Cannavale et al ’ JVIR1062 ’ Updated Management of Malignant Biliary Tract Tumorsdiffuse asymmetric gallbladder wall thickening (stage
T1–T3), or (iii) a mass completely occupying or
replacing the gallbladder lumen (stage T3–T4; Fig 5)
(3,24). Obstruction of the extrahepatic bile ducts causingjaundice may occur as a result of intraductal spread
along the cystic duct toward the perihilar region (simu-
lating pCC) that is considered to represent stage T3
disease (stage III). At this stage, the tumor may be
Table 5 . AJCC 7th Edition Staging System for Gallbladder Adenocarcinoma
Final
Stage Tumor Stage Node Stage Metastasis Stage
IA T1: tumor invades lamina propria or muscular layer N0: no regional lymph node
metastasis
M0: no distant metastasis
II T2: tumor invades perimuscular connective tissue; no
extension beyond serosa or into liver
N0: no regional lymph node
metastasis
M0: no distant metastasis
III T3: tumor perforates serosa (visceral peritoneum) and/or
directly invades liver and/or one other adjacent organ or
structure, eg, stomach, duodenum, colon, pancreas,
omentum, or extrahepatic bile ducts
N0: no regional lymph node
metastasis
M0: No distant metastasis
IVA T4: tumor invades main PV or hepatic artery or invades two
or more extrahepatic organs or structures
N0: no regional lymph node
metastasis
M0: no distant metastasis
Any N1: regional lymph node
metastasis
M0: no distant metastasis
IVB Any Any M1: distant metastasis
AJCC ¼ American Joint Committee on Cancer; PV ¼ portal vein.
Figure 5. Images from a 71-year-old woman referred with jaundice and colic pain. (a) T2-weighted axial MR image shows the mass
arising from the thickened gallbladder wall (arrow), invading segments IV/V. (b) Delayed fat-saturated T1-weighted postcontrast image
shows retention of gadobenate dimeglumine within the tumor. (c) Coronal CT view demonstrates a hepatic lesion that infiltrates the
right colic flexure. (d) Axial CT image in portal-venous phase shows infiltration of the right PV branch (arrows). The tumor was classified
as stage IVA (T4N0M0). (e) PTC shows tight subhilar stricture of the CBD. (f) Bilateral self-expandable metal stents were inserted
percutaneously to allow bilirubin normalization and chemotherapy administration.
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Cannavale et al ’ JVIR1064 ’ Updated Management of Malignant Biliary Tract Tumorsconsidered “borderline” resectable, although the final
decision is to be made on a multidisciplinary basis.
Local lymph nodes are involved in 50% of patients at
diagnosis (stage N1); involvement of distant lymph nodes
is considered to represent stage N2 disease and is
associated with the worst prognosis (stage IVB), similar
to cases of distant metastases (stage M1) (4). Management
according to respective staging is depicted in Figure 6.CC and GBA: Clinical Management and
Therapeutic Options
Presenting symptoms may vary according to the extent
of disease: clinical presentation of iCC is rarely accom-
panied by jaundice caused by obstruction of bile ducts
unless it extends to the hilum, CBD, or enlarged
metastatic lymph nodes, causing hilar compression.
The most common presentation of iCC is characterized
by nonspecific symptoms such as abdominal pain, weak-
ness, night sweating, and cachexia.Figure 6. Flowchart showing clinical/radiologic management of GB
involvement and distant metastasis, but it does not have a definite ro
CRT ¼ chemoradiation therapy; LFT ¼ liver function test; MRCP ¼ m
metal stent.Extrahepatic tumors and GBA may cause symptoms
and signs of biliary obstruction, including pruritus and
jaundice, that often present belatedly. In particular, GBA
can mimic symptoms of biliary colic and chronic chol-
ecystitis. Additionally, recurrent cholangitis, intrahepatic
bile duct stones, and abnormal liver function may coexist.
Interestingly, fever is more frequently apparent in pCC
than dCC. Predominant clinical patterns of presentation
are (i) incidental mass or obstruction signs on imaging
and (ii) presence of symptoms (3).
Patients with iCC, eCC, or GBA, should be initially
assessed in a consultation that includes clinical exami-
nation, liver function tests, cancer antigen assessment
(carcinoembryonic antigen, cancer antigen 19.9), and
imaging such as MR cholangiopancreatography and
CT. In iCC cases, preoperative biopsy, diagnostic
laparoscopy to exclude unresectable disseminated dis-
ease, esophagogastroduodenoscopy, colonoscopy, and
hepatitis serology may be considered. In extrahepatic
CC, additional endoscopic ultrasound (US) for localA. PET/CT may contribute to staging by detecting lymph node
le yet. CA ¼ cancer antigen; CEA ¼ carcinoembryonic antigen;
agnetic resonance pancreatography; SEMS ¼ self-expandable
Volume 27 ’ Number 7 ’ July ’ 2016 1065staging may be appropriate. Following assessment, CC
and GBA may be classified as resectable, unresectable,
or metastatic. Clinical/radiologic management is illus-
trated in Figures 6–8.
Resectable disease. If the iCC or pCC is resectable,
the patient can undergo a lobar, segmental, or wedge
resection with portal lymphadenectomy, which is
considered useful for appropriate treatment and stag-
ing information (4). Otherwise, dCC is treated with
pancreaticoduodenectomy, often with lymphadenec-
tomy and resection of the nerve plexus alongside major
vessels (25). Preoperative biliary drainage (PBD) before
resection may be indicated (25).
In resectable GBA, cholecystectomy and en bloc
hepatic resection (resection of segments IV/V), lympha-
denectomy, and/or bile duct excision represents the
surgical approach of choice. An extended hepatic or bile
duct resection may be necessary to guarantee an R0
margin (4,26). The role of extended regional lymphade-
nectomy on clinical outcome remains equivocal (27).
Five-year disease-free survival rates after GBA resection
have been reported to be as high as 65% (28).Figure 7. Flowchart showing clinical/radiologic management of iC
involvement and distant metastasis, but it does not have a definite role
¼ chemoradiation therapy; EGDS = esophagogastroduodenoscop
pancreatography; SEMS ¼ self-expandable metal stent.PBD is a subject of contentious discussion. The
primary drawbacks include increased perioperative risk
of cholangitis, neoplastic seeding, and bleeding (13).
Moreover, PBD may significantly increase the duration
of hospital stay (27,28). There remains limited published
literature regarding the influence of PBD on quality of
life. The current evidence on PBD is insufficient to
support or refute routine preoperative biliary drainage
for patients with obstructive jaundice. Consequently,
systematic preoperative biliary drainage is not recom-
mended, but may be appropriate in selected patients
(27–29). Benefits of internal PBD include correction of
nutritional and biochemical abnormalities before sur-
gery. In pCC, it permits time to perform PV emboliza-
tion (PVE) in an effort to increase the future remnant
liver (FRL) (3,4). There is inadequate evidence to
demonstrate whether PVE increases resectability,
achievement of R0 margin, or survival (29–32).
International endoscopic guidelines advise that PBD
in hilar strictures caused by pCC (Bismuth class Z 2) or
GBA should be performed via percutaneous route
instead of via ERCP. However, in patients with dCC,
preoperative drainage should be first attempted withC. PET/CT may contribute to staging detecting lymph node
yet. CA ¼ cancer antigen; CEA ¼ carcinoembryonic antigen; CRT
y; LFT ¼ liver function test; MRCP ¼ magnetic resonance
Figure 8. Flowchart showing clinical/radiologic management of extrahepatic CC. pCC is staged based on Jarnagin–Blumgart staging
and AJCC Seventh Edition staging. Note that OLT is suitable only in selected patients with pCC (see text). CA ¼ cancer antigen; CEA ¼
carcinoembryonic antigen; CRT ¼ chemoradiation therapy; LFT ¼ liver function test; MRCP ¼ magnetic resonance pancreatography;
SEMS ¼ self-expandable metal stent.
Cannavale et al ’ JVIR1066 ’ Updated Management of Malignant Biliary Tract TumorsERCP and sphincterotomy. In particular, placement of
short covered stents distal to the biliary bifurcation
(leaving at least 2 cm of the common hepatic duct below
the bifurcation) does not affect the technical outcome of
the duodenopancreatectomy and the biliary anastomosis
(3,11–13,32–34). It is recognized that surgical resection is
no more complex when performed in the presence of a
short bare metal stent rather than a plastic stent (34).
Current recommendations advise PBD to be performed
in (i) candidates for neoadjuvant therapies (ii) acute
cholangitis and liver/renal disfunction (iii) intense pruritus
and delayed surgery (iv) allow PVE to improve FRL and
allow surgical resection (11–13,29,30,32). In the case of R0
resection or microscopic residual disease or positive
regional nodes, the patient should undergo adjuvant
treatment and clinical imaging follow-up every 6 months
for 2 years if clinically appropriate. If there is macroscopic
residual disease after resection, the patient should undergo
adjuvant therapy alone (4). Therapy-related outcomes in
resectable MBTs are shown in Table 6 (3,15,24,25,29–31).
Unresectable/metastatic disease. In patients with
unresectable or metastatic disease, subsequent manage-
ment may involve interventional radiologic techniques.
Patients with extrahepatic CC and GBA may require atissue diagnosis, and endoluminal biopsy in CC is often
necessary. Percutaneous transhepatic cholangiography
(PTC) with metallic stent placement should be the first
palliative intervention in view of the higher success
rate of initial biliary drainage compared with ERCP
(11–13,30,35).
In patients with inoperable dCC, biliary drainage
should be attempted endoscopically first: initial insertion
of a 10-F plastic stent is recommended if the diagnosis of
malignancy is not established or if expected survival is
less than 4 months. In patients with an established
diagnosis of malignancy, initial insertion of a 10-mm-
diameter self-expandable metal stent is recommended if
expected survival is greater than 4 months (11–13). Only
when an endoscopic approach fails, a percutaneous
approach with PTC and subsequent stent insertion
should be considered (11). Covered stents and partially
covered stents demonstrated longer patency times than
uncovered stents, with a low risk of migration (36–38).
The most important factor affecting survival is the
normalization—not only improvement—of bilirubin lev-
els (39,40). A survival analysis (41) identified that
survival rates were significantly higher in patients with
total bilirubin levels lower than 4 mg/dL compared
with patients with higher postoperative bilirubin levels
Table 6 . Resectable Malignant Biliary Tumors and GBA: Resuming Treatments and Outcomes (3,15,24,25,29–31)
Staging Therapy Outcome
GBA Stage 0–II (III) Extended gallbladder resection 5-y disease-free survival rate as high as 65% (24)
Intrahepatic CC (stage I–III) Resection and lymphadenectomy 5-y survival 31% (15)
Perihilar CC (stage 0–II) Liver resection with/without bile duct resection
with/without PBD
2-y survival 87.4% (3); 5-y survival 22%–50% with R0
and 0%–20% with R1 (29–31)
PVE and PBD, then surgical resection PVE increases resection rate (29–31); similar overall
survival vs non-PVE surgery (29,30)
Distal CC (stage 0–II) Pancreaticoduodenectomy with/without
lymphadenectomy with/without PBD
5-y median survival 37% (25)
CC ¼ cholangiocarcinoma; GBA ¼ gallbladder adenocarcinoma; PBD ¼ preoperative biliary drainage; PVE ¼ portal vein embolization;
R0 ¼ resection margin negative; R1 ¼ resection margin positive for local disease.
Volume 27 ’ Number 7 ’ July ’ 2016 1067with whole or partial liver drainage. The British Biliary
Drainage and Stenting Registry (42) outlined that, in
patients with proximal hilar lesions, bilateral drainage or
stent implantation resulted in a significantly greater
reduction in bilirubin level (76.2%) than when only one
lobe of the liver was drained or treated with a stent
(34.4%; P ¼ .001). Together, these findings suggest that
the optimal approach to patients with a hilar stricture is
to attempt bilateral drainage in the first place (35). Relief
of obstruction with a stent may palliate pain, resolve
cholangitis, and improve quality of life, and may be
beneficial in the context of chemotherapy.
Available treatment options for unresectable or meta-
static disease include (i) clinical trials, (ii) fluoropyrimidine-
or gemcitabine-based chemotherapy or fluoropyrimidine
chemoradiation, (iii) best supportive care, and (iv) ortho-
topic liver transplantation (OLT) (4). In addition, patients
with iCC may also be suitable candidates for interventional
radiologic treatments, including radiofrequency ablation,
transarterial chemoembolization, drug-eluting bead chemo-
embolization, and transarterial radioembolization with
yttrium 90 (90Y). Ipsilateral PVE to increase the FRL
followed by resection may also represent a valid therapeu-
tic option to reserve for selected patients (3).
OLT is the last curative resource for unresectable pCC
with negative lymph nodes and no metastatic disease: the
survival rate may be as high as 42% at 5 years (3).
Advantages of OLT over resection include the potential
treatment of otherwise unresectable disease (Bismuth IV,
stage IIIA/IVA, N0, M0) and the treatment of patients with
underlying chronic liver disease (13). Notably, biopsy is not
indicated before OLT because of the risk of neoplastic
seeding. A new protocol combining neoadjuvant chemo-
radiation therapy and OLT yielded 5-year survival rates as
high as 70% (43), but future research in this field is required
(4). Therapy-related outcomes in unresectable/metastatic
MBTs are shown in Table 7 (2,23,38,43–46).FUTURE CHALLENGES
Recent advances in imaging techniques and targeted and
minimally invasive therapies are at the forefront of thefuture management of biliary tract tumors. Increasingly
used imaging techniques include positron emission
tomography (PET)/CT and endoscopic US. Current
evidence suggests that the role of PET imaging in CC
and GBA is not yet established, but concordant studies
indicate that it has a role in detecting regional nodal
metastasis or distant metastases in patients with other-
wise resectable disease (3,47). Hence, it may have the
potential to replace staging laparoscopy.
Endoscopic US is mainly indicated in extrahepatic CC
and is more accurate than US and CT in the diagnosis
and staging of malignant biliary obstruction (75% with
endoscopic US vs 38% with US and 62% with CT) (48).
Recently, endoscopic US showed at least comparable
sensitivity—Weilert et al (49) reported 79% sensitivity
for both techniques—in tissue sampling of
extrapancreatic CC; however, there are low negative
predictive values of 29%–67% and a higher risk of false-
negative results in patients with a high degree of
suspicion of malignancy (49). However, endoscopic US
has an increasing role in clinical decision-making in
cases of CC, allowing improved assessment of metastatic
lymph nodes (ie, N stage) and local invasion (ie, T stage)
and in providing a differential diagnosis in indeter-
minate biliary strictures (48). An evolving application
of endoscopic US concerns endoscopic US–guided
biliary drainage to be performed when ERCP fails.
Currently, this technique is still in its infancy and is
practiced only at specialized tertiary centers (50). As a
consequence, percutaneous biliary drainage remains the
principal alternative treatment (4).
Interventional radiology can offer a number of appli-
cations in patients with CC: newer embolization techni-
ques such as chemoembolization with DC-Bead (BTG,
London, United Kingdom) (44,45) and 90Y radioembo-
lization (46) are now valuable options in unresectable
iCC. Median survival after radioembolization is 15.5
months, which is actually similar to that after systemic
cisplatin/gemcitabine chemotherapy (11.7 mo) and
chemoembolization (13.4 mo). Therefore, further
studies are necessary to define the role and efficacy of
those techniques. Stronger evidence is available for pre-
operative PVE associated with biliary drain insertion in
Table 7 . Unresectable and Metastatic Malignant Biliary Tumors and GBA: Resuming Treatments and Outcomes (2,23,38,43–46)
Staging Therapy Biliary Stent Patency Outcome (Survival)
GBA (stage III/IV, M1) Biliary drainage (SEMS);
chemotherapy, chemoradiation
Similar to pCC (studies include
pCC and GBA)
5-y survival up to 5% (23)
Intrahepatic CC (stage
III/IV)
Chemoembolization/
radioembolization or
chemotherapy
NA Chemotherapy, 11.7 mo (3);
chemoembolization, 13.4 mo
(44,45); radioembolization, 15.5
mo (46)
pCC (stage III/IV, M0/1) Biliary drainage; chemotherapy,
chemoradiation
Cumulative patency rate (BMS):
69.4% at 3 mo; 44.4% at 6 mo (35)
Median survival 7.9–14.6 mo; 1-y
survival up to 12.9% (3)
pCC (stage III/IV, M0) OLT NA 5-y survival up to 42% (3)
Neoadjuvant chemoradiation, OLT
(43)
5-y survival 65%–70% (43)
Distal CC (stage III/IV, M1) Biliary drainage (BMS/CMS);
chemotherapy, chemoradiation
BMS (193–285d); CMS (225–357 d)
(38)
Median survival: BMS, 180.5–184 d
(38); CMS, 222–227.3 d (38)
BMS ¼ bare metal stent; CC ¼ cholangiocarcinoma; CMS ¼ covered metal stent; GBA ¼ gallbladder adenocarcinoma; NA ¼ not
applicable; OLT ¼ orthotopic liver transplantation; pCC ¼ perihilar cholangiocarcinoma; SEMS ¼ self-expandable metal stent.
Cannavale et al ’ JVIR1068 ’ Updated Management of Malignant Biliary Tract Tumorspatients with jaundice and resectable hilar CC and GBA
to increase the FRL (46,51,52).
Finally, molecular-targeted therapy has the expect-
ation of replacing and improving outcomes of conven-
tional chemotherapy. Ongoing phase II and III trials are
demonstrating promising results for drugs with different
molecular targets (eg, erlotinib, lapatinib, sorafenib, and
selumetinib) alone and in combination with conven-
tional chemotherapy (53).CONCLUSIONS
Current management of MBTs is influenced by contin-
uous progression in imaging and therapeutic techniques.
Updated imaging and clinical guidelines may help the
clinician and the radiologist to select the appropriate
pathway of workup and treatment. The primary aim
remains to deliver the optimum treatment, whether it is
curative resection, transplantation, or palliation, to
ultimately improve outcome and quality of life.REFERENCES
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